Gilead Sciences launch one-pill, combination HIV treatment ‘Genvoya’

‘Genvoya,’ a one-pill, combination HIV treatment containing TAF(Tenofovir Alafenamide) for the first time, will be launched in Korea from February.

Tenofovir Alafenamide shows the antiviral effect that is similar to the existing tenofovir disoproxil fumarate(TDF) with the 90% lesser volume and is a targeted prodrug which improves the side effects caused by tenofovir to kidney and bone through ...